Surface Oncology to Present at the American Society of Clinical Oncology Annual Meeting

Rhea-AI Summary

Surface Oncology (Nasdaq: SURF) announced that data from the Phase 1 study of SRF231, a high-affinity anti-CD47 antibody, will be presented at the ASCO 2020 Annual Meeting, occurring virtually from May 29-31. The presentation type is an e-poster with the abstract number 3064. The lead author is Amita Patnaik, and the session will focus on Developmental Therapeutics - Immunotherapy. Although the SRF231 clinical program was deprioritized in 2018, the Phase 1 study is now concluding. For full details, the poster will be available on Surface Oncology’s website after the presentation.

CAMBRIDGE, Mass., May 14, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that data from the Phase 1 study of SRF231, a fully human, high-affinity anti-CD47 antibody, will be presented at the American Society of Clinical Oncology (ASCO) 2020 Annual Meeting, to be held virtually May 29-31.

A summary is provided below; the full poster will be placed on Surface Oncology’s website following the presentation.

Presentation Type: e-poster (Abstract: 3064 / Poster: 128)
Title: Results of a first-in-human Phase 1 study of SRF231, a fully human, high-affinity anti-CD47 antibody
Lead Author: Amita Patnaik
Session: Developmental Therapeutics - Immunotherapy

In 2018, Surface Oncology deprioritized the SRF231 clinical program and is concluding its Phase 1 study.

About Surface Oncology:
Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment. Its pipeline includes two wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), a clinical-stage collaboration with Novartis targeting CD73 (NZV930), and two preclinical programs, each focused primarily on activating natural killer cells (via targeting CD112R) or depleting regulatory T cells (via targeting CCR8). Surface’s novel cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies. For more information, please visit www.surfaceoncology.com.

Contacts:
Investors
Matt Lane
matt@gilmartinir.com
617-901-7698

Media
Tom Donovan
tom@tenbridgecommunications.com
857-559-3397

FAQ

What is the date of the ASCO 2020 Annual Meeting for SURF?

The ASCO 2020 Annual Meeting will be held virtually from May 29-31.

What is the focus of Surface Oncology's presentation at ASCO 2020?

The presentation will focus on the Phase 1 study results of SRF231, a high-affinity anti-CD47 antibody.

Who is the lead author for the SURF presentation at ASCO 2020?

The lead author for the presentation is Amita Patnaik.

What type of presentation will Surface Oncology have at ASCO 2020?

Surface Oncology will present an e-poster at ASCO 2020.

What is SRF231's clinical status as mentioned in the Surface Oncology press release?

SRF231 is in the concluding phase of its Phase 1 study.